Tuesday November 24 2009 | Biotechnology feed | All feeds

BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease

Adeza

Adeza is a medical technology company located in Sunnyvale, California. Adeza’s products are recognized worldwide through both direct sales and distribution in over 20 countries. Adeza’s product focus is on proprietary tests and services for the diagnosis of pregnancy-related and female reproductive disorders including premature birth and infertility. In the U.S., preterm birth is the leading cause of perinatal mortality and morbidity with healthcare costs exceeding $18.1 billion annually. Adeza received an expedited premarket approval from the U.S. Food and Drug Administration (FDA) to market the proprietary FullTerm™, The Fetal Fibronectin Test. FullTerm™, The Fetal Fibronectin Test detects a protein found in pregnant women and is used as an aid in the assessment of the risk of premature birth from 22 to 35 weeks of pregnancy. The FullTerm™, Fetal Fibronectin Test has demonstrated effectiveness in 125+ published peer-reviewed studies and is available on Adeza’s TLiIQ® System.


Contact Details:
1240 Elko Drive
Sunnyvale
California
94089
United States of America
Tel:1.408.745.0975
Fax:1.408.745.0208
Email:customerservice@adeza.com
WWW:

www.adeza.com/




Loading...

Press Releases on Adeza:

BioPortfolio Logo
Reportlinker Adds Point of Care Diagnostics 2010 and Beyond: Rapid Testing at a Crossroads 5th November, 2009 Reportlinker
NEW YORK, Nov. 5 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue. Point of Care Diagnostics 2010 and Beyond: Rapid Testing at a Crossroads
Hologic Announces Third Quarter Fiscal 2008 Operating Results 30th July, 2008 Hologic, Inc.
BEDFORD, Mass., July 30 /PRNewswire-FirstCall/ -- Hologic, Inc. (Nasdaq: HOLX), a diversified medical technologies company specializing in diagnostics, imaging products and interventional devices

Adeza Clinical Trials:

fFN & E3 in the Prediction of PTB in Women With Twin Pregnancies Receiving 17OHP or Placebo

Adeza Patents:

US Patent No.Title
7270970 Point of care diagnostic systems
5468619 Screening method for identifying women at increased risk for imminent delivery
5281522 Reagents and kits for determination of fetal fibronectin in a vaginal sample
5236846 Ectopic pregnancy test
5223440 Ex vivo product of conception test to determine abortion

View more Adeza patents.

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 990 times since April 2007, the link to the organisation's website has been followed 205 times

Recent Search Terms used to find this page: HOLOGIC RAPID fFN TEST | fullterm fibronectin sales hologic | adeza fetal fibronectin | adeza | hologic adeza ffn fda reports | adeza website | Adeza patents | adeza fetal fibronectin test | adeza logo | ADEZA | .

Search for more companies in Sunnyvale

Search for more companies in California



This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for Adeza

 

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.

All rights reserved. All other trademarks recognized.
Copyright 1997-2009 - BioPortfolio Limited.